Declared Dividend • Jun 01
Dividend of CN¥0.50 announced Shareholders will receive a dividend of CN¥0.50. Ex-date: 3rd June 2026 Payment date: 3rd June 2026 Dividend yield will be 2.6%, which is higher than the industry average of 1.6%. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months. The dividend is also not covered by cash flows (118% cash payout ratio). The dividend has increased by an average of 14% per year over the past 4 years. However, payments have been volatile during that time. Reported Earnings • Apr 23
First quarter 2026 earnings released: EPS: CN¥0.01 (vs CN¥0.005 in 1Q 2025) First quarter 2026 results: EPS: CN¥0.01 (up from CN¥0.005 in 1Q 2025). Revenue: CN¥320.6m (up 13% from 1Q 2025). Net income: CN¥4.18m (up 119% from 1Q 2025). Profit margin: 1.3% (up from 0.7% in 1Q 2025). The increase in margin was driven by higher revenue. Revenue is forecast to grow 26% p.a. on average during the next 2 years, compared to a 13% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings. Announcement • Apr 23
Nanjing Vazyme Biotech Co., Ltd, Annual General Meeting, May 13, 2026 Nanjing Vazyme Biotech Co., Ltd, Annual General Meeting, May 13, 2026, at 14:30 China Standard Time. Location: The Company's Meeting Room, Nanjing, Jiangsu China Announcement • Mar 30
Nanjing Vazyme Biotech Co., Ltd to Report Q1, 2026 Results on Apr 23, 2026 Nanjing Vazyme Biotech Co., Ltd announced that they will report Q1, 2026 results on Apr 23, 2026 Reported Earnings • Mar 04
Full year 2025 earnings: EPS and revenues miss analyst expectations Full year 2025 results: CN¥0.04 loss per share (improved from CN¥0.05 loss in FY 2024). Revenue: CN¥1.38b (flat on FY 2024). Net loss: CN¥17.0m (loss narrowed 6.2% from FY 2024). Revenue missed analyst estimates by 6.2%. Earnings per share (EPS) were also behind analyst expectations. Revenue is forecast to grow 19% p.a. on average during the next 2 years, compared to a 16% growth forecast for the Biotechs industry in China. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 46 percentage points per year, which is a significant difference in performance. Announcement • Dec 26
Nanjing Vazyme Biotech Co., Ltd to Report Fiscal Year 2025 Results on Apr 23, 2026 Nanjing Vazyme Biotech Co., Ltd announced that they will report fiscal year 2025 results on Apr 23, 2026 Reported Earnings • Oct 30
Third quarter 2025 earnings released: EPS: CN¥0.01 (vs CN¥0.007 in 3Q 2024) Third quarter 2025 results: EPS: CN¥0.01 (up from CN¥0.007 in 3Q 2024). Revenue: CN¥346.2m (up 2.8% from 3Q 2024). Net income: CN¥3.49m (up 75% from 3Q 2024). Profit margin: 1.0% (up from 0.6% in 3Q 2024). Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in China. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 80 percentage points per year, which is a significant difference in performance. Announcement • Sep 30
Nanjing Vazyme Biotech Co., Ltd to Report Q3, 2025 Results on Oct 30, 2025 Nanjing Vazyme Biotech Co., Ltd announced that they will report Q3, 2025 results on Oct 30, 2025 Buy Or Sell Opportunity • Aug 14
Now 21% undervalued Over the last 90 days, the stock has risen 15% to CN¥25.40. The fair value is estimated to be CN¥32.14, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 31% over the last 3 years. Meanwhile, the company became loss making. Buy Or Sell Opportunity • Jul 30
Now 21% undervalued Over the last 90 days, the stock has risen 15% to CN¥25.39. The fair value is estimated to be CN¥32.05, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 31% over the last 3 years. Meanwhile, the company became loss making. Announcement • Jun 30
Nanjing Vazyme Biotech Co., Ltd to Report First Half, 2025 Results on Aug 29, 2025 Nanjing Vazyme Biotech Co., Ltd announced that they will report first half, 2025 results on Aug 29, 2025 Buy Or Sell Opportunity • May 03
Now 21% undervalued Over the last 90 days, the stock has risen 9.4% to CN¥22.07. The fair value is estimated to be CN¥27.90, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 31% over the last 3 years. Meanwhile, the company became loss making. Announcement • Apr 29
Nanjing Vazyme Biotech Co., Ltd, Annual General Meeting, May 19, 2025 Nanjing Vazyme Biotech Co., Ltd, Annual General Meeting, May 19, 2025, at 14:30 China Standard Time. New Risk • Apr 15
New major risk - Dividend sustainability The dividend is not well covered by earnings and cash flows. Payout ratio: 201% The company is paying a dividend despite having no free cash flows. Dividend yield: 1.2% This is considered a major risk. Companies that pay out too much of their earnings and cash flows are at risk of having to reduce or cut their dividend in future. If earnings or cash flows stagnate or fall, then there may not be enough to maintain the same dividend. Or in extreme cases, companies may opt to dig into capital reserves or take on debt to maintain the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. This is currently the only risk that has been identified for the company. Reported Earnings • Apr 11
Full year 2024 earnings: EPS and revenues miss analyst expectations Full year 2024 results: CN¥0.05 loss per share (improved from CN¥0.18 loss in FY 2023). Revenue: CN¥1.38b (up 7.1% from FY 2023). Net loss: CN¥18.1m (loss narrowed 75% from FY 2023). Revenue missed analyst estimates by 7.5%. Earnings per share (EPS) were also behind analyst expectations. Revenue is forecast to grow 23% p.a. on average during the next 2 years, compared to a 24% growth forecast for the Biotechs industry in China. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 66 percentage points per year, which is a significant difference in performance. Announcement • Mar 28
Nanjing Vazyme Biotech Co., Ltd to Report Q1, 2025 Results on Apr 29, 2025 Nanjing Vazyme Biotech Co., Ltd announced that they will report Q1, 2025 results on Apr 29, 2025 Reported Earnings • Mar 04
Full year 2024 earnings: EPS and revenues miss analyst expectations Full year 2024 results: CN¥0.04 loss per share (improved from CN¥0.18 loss in FY 2023). Revenue: CN¥1.37b (up 6.6% from FY 2023). Net loss: CN¥17.0m (loss narrowed 76% from FY 2023). Revenue missed analyst estimates by 7.5%. Earnings per share (EPS) were also behind analyst expectations. Revenue is forecast to grow 23% p.a. on average during the next 2 years, compared to a 25% growth forecast for the Biotechs industry in China. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 68 percentage points per year, which is a significant difference in performance. Announcement • Dec 27
Nanjing Vazyme Biotech Co., Ltd to Report Fiscal Year 2024 Results on Apr 10, 2025 Nanjing Vazyme Biotech Co., Ltd announced that they will report fiscal year 2024 results on Apr 10, 2025 Reported Earnings • Oct 31
Third quarter 2024 earnings released: EPS: CN¥0.007 (vs CN¥0.012 in 3Q 2023) Third quarter 2024 results: EPS: CN¥0.007 (down from CN¥0.012 in 3Q 2023). Revenue: CN¥336.6m (up 13% from 3Q 2023). Net income: CN¥2.00m (down 57% from 3Q 2023). Profit margin: 0.6% (down from 1.6% in 3Q 2023). Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 26% growth forecast for the Biotechs industry in China. New Risk • Sep 30
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 7.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.9% average weekly change). Large one-off items impacting financial results. Announcement • Sep 30
Nanjing Vazyme Biotech Co., Ltd to Report Q3, 2024 Results on Oct 31, 2024 Nanjing Vazyme Biotech Co., Ltd announced that they will report Q3, 2024 results on Oct 31, 2024 Reported Earnings • Aug 29
Second quarter 2024 earnings released: EPS: CN¥0.038 (vs CN¥0.072 loss in 2Q 2023) Second quarter 2024 results: EPS: CN¥0.038 (up from CN¥0.072 loss in 2Q 2023). Revenue: CN¥347.7m (up 29% from 2Q 2023). Net income: CN¥10.9m (up CN¥41.4m from 2Q 2023). Profit margin: 3.1% (up from net loss in 2Q 2023). Revenue is forecast to grow 28% p.a. on average during the next 2 years, compared to a 24% growth forecast for the Biotechs industry in China. Announcement • Jun 28
Nanjing Vazyme Biotech Co.,Ltd to Report First Half, 2024 Results on Aug 29, 2024 Nanjing Vazyme Biotech Co.,Ltd announced that they will report first half, 2024 results on Aug 29, 2024 Announcement • May 17
Nanjing Vazyme Biotech Co.,Ltd, Annual General Meeting, Jun 06, 2024 Nanjing Vazyme Biotech Co.,Ltd, Annual General Meeting, Jun 06, 2024, at 14:30 China Standard Time. Location: The Company's Meeting Room, Nanjing, Jiangsu China Reported Earnings • Apr 28
First quarter 2024 earnings released: EPS: CN¥0.01 (vs CN¥0.13 loss in 1Q 2023) First quarter 2024 results: EPS: CN¥0.01 (up from CN¥0.13 loss in 1Q 2023). Revenue: CN¥301.6m (flat on 1Q 2023). Net income: CN¥5.22m (up CN¥55.8m from 1Q 2023). Profit margin: 1.7% (up from net loss in 1Q 2023). Revenue is forecast to grow 25% p.a. on average during the next 2 years, compared to a 24% growth forecast for the Biotechs industry in China. New Risk • Apr 15
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (11% average weekly change). Announcement • Mar 30
Nanjing Vazyme Biotech Co.,Ltd to Report Q1, 2024 Results on Apr 27, 2024 Nanjing Vazyme Biotech Co.,Ltd announced that they will report Q1, 2024 results on Apr 27, 2024 Reported Earnings • Feb 29
Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2023 results: CN¥0.18 loss per share (down from CN¥1.49 profit in FY 2022). Revenue: CN¥1.29b (down 64% from FY 2022). Net loss: CN¥70.7m (down 112% from profit in FY 2022). Revenue exceeded analyst estimates by 1.8%. Earnings per share (EPS) missed analyst estimates. Revenue is forecast to grow 25% p.a. on average during the next 2 years, compared to a 22% growth forecast for the Biotechs industry in China. Price Target Changed • Feb 22
Price target decreased by 52% to CN¥35.72 Down from CN¥74.95, the current price target is provided by 1 analyst. New target price is 45% above last closing price of CN¥24.70. Stock is down 55% over the past year. The company is forecast to post earnings per share of CN¥0.15 for next year compared to CN¥1.49 last year. Announcement • Feb 06
Nanjing Vazyme Biotech Co.,Ltd (SHSE:688105) announces an Equity Buyback for CNY 160 million worth of its shares. Nanjing Vazyme Biotech Co., Ltd. (SHSE:688105) announces a share repurchase program. Under the program, the company will repurchase CNY 160 million worth of its shares. The shares will be purchased at a price not exceeding CNY 30 per share. The repurchased shares will be used for the implementation of ESOP or equity incentive plan. The program will be valid for 12 months. New Risk • Nov 30
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Chinese stocks, typically moving 8.0% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.0% average weekly change). Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Cash payout ratio: 329% Reported Earnings • Nov 01
Third quarter 2023 earnings released: EPS: CN¥0.012 (vs CN¥0.34 in 3Q 2022) Third quarter 2023 results: EPS: CN¥0.012 (down from CN¥0.34 in 3Q 2022). Revenue: CN¥298.3m (down 56% from 3Q 2022). Net income: CN¥4.70m (down 97% from 3Q 2022). Profit margin: 1.6% (down from 20% in 3Q 2022). Revenue is forecast to grow 6.8% p.a. on average during the next 3 years, compared to a 24% growth forecast for the Biotechs industry in China. New Risk • Oct 18
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 6.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Cash payout ratio: 396% Minor Risk Share price has been volatile over the past 3 months (6.3% average weekly change). Reported Earnings • Aug 30
Second quarter 2023 earnings: EPS and revenues miss analyst expectations Second quarter 2023 results: CN¥0.072 loss per share (down from CN¥0.45 profit in 2Q 2022). Revenue: CN¥268.8m (down 58% from 2Q 2022). Net loss: CN¥30.5m (down 117% from profit in 2Q 2022). Revenue missed analyst estimates by 17%. Earnings per share (EPS) were also behind analyst expectations. Revenue is forecast to grow 5.3% p.a. on average during the next 3 years, compared to a 23% growth forecast for the Biotechs industry in China. Announcement • Aug 23
Nanjing Vazyme Biotech Co., Ltd. (SHSE:688105) announces an Equity Buyback for CNY 30 million worth of its shares. Nanjing Vazyme Biotech Co., Ltd. (SHSE:688105) announces a share repurchase program. Under the program, the company will repurchase its A shares for a total of CNY 30 million. The shares will be purchased at a price not exceeding CNY 45 per share. The repurchased shares will be used for the implementation of ESOP or equity incentive plan. If the company fails to use the shares for the aforementioned purposes within 3 years from the date of completion of program, the unused portion of the repurchased shares shall be cancelled. The program will be funded from company's own funds. The program will be valid for 12 months. Announcement • Jun 28
Nanjing Vazyme Biotech Co., Ltd. to Report First Half, 2023 Results on Aug 30, 2023 Nanjing Vazyme Biotech Co., Ltd. announced that they will report first half, 2023 results on Aug 30, 2023 New Risk • Jun 13
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 6.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Dividend is not well covered by earnings and cash flows. Payout ratio: 441% Paying a dividend despite having no free cash flows. Minor Risks Share price has been volatile over the past 3 months (6.7% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (3.9% net profit margin). Major Estimate Revision • May 27
Consensus EPS estimates increase by 130% The consensus outlook for fiscal year 2023 has been updated. 2023 EPS estimate increased from CN¥0.61 to CN¥1.40. Revenue forecast steady at CN¥1.49b. Net income forecast to grow 468% next year vs 37% growth forecast for Biotechs industry in China. Consensus price target of CN¥64.56 unchanged from last update. Share price was steady at CN¥34.17 over the past week. Major Estimate Revision • May 09
Consensus EPS estimates fall by 41% The consensus outlook for earnings per share (EPS) in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from CN¥1.59b to CN¥1.48b. EPS estimate also fell from CN¥1.30 per share to CN¥0.76 per share. Net income forecast to grow 707% next year vs 38% growth forecast for Biotechs industry in China. Consensus price target down from CN¥74.95 to CN¥64.56. Share price fell 5.0% to CN¥35.18 over the past week. Reported Earnings • Apr 28
First quarter 2023 earnings released: CN¥0.13 loss per share (vs CN¥1.08 profit in 1Q 2022) First quarter 2023 results: CN¥0.13 loss per share (down from CN¥1.08 profit in 1Q 2022). Revenue: CN¥302.2m (down 69% from 1Q 2022). Net loss: CN¥50.6m (down 112% from profit in 1Q 2022). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 24% growth forecast for the Biotechs industry in China. Reported Earnings • Mar 01
Full year 2022 earnings released: EPS: CN¥1.63 (vs CN¥1.87 in FY 2021) Full year 2022 results: EPS: CN¥1.63 (down from CN¥1.87 in FY 2021). Revenue: CN¥3.58b (up 91% from FY 2021). Net income: CN¥651.4m (down 4.0% from FY 2021). Profit margin: 18% (down from 36% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to stay flat during the next 3 years compared to a 24% growth forecast for the Biotechs industry in China. Valuation Update With 7 Day Price Move • Dec 22
Investor sentiment deteriorated over the past week After last week's 16% share price decline to CN¥55.77, the stock trades at a forward P/E ratio of 24x. Average forward P/E is 27x in the Biotechs industry in China. Total loss to shareholders of 54% over the past year. Simply Wall St's valuation model estimates the intrinsic value at CN¥88.62 per share. Valuation Update With 7 Day Price Move • Nov 29
Investor sentiment improved over the past week After last week's 18% share price gain to CN¥75.74, the stock trades at a forward P/E ratio of 33x. Average forward P/E is 28x in the Biotechs industry in China. Total loss to shareholders of 35% over the past year. Simply Wall St's valuation model estimates the intrinsic value at CN¥96.07 per share. Price Target Changed • Nov 16
Price target decreased to CN¥90.14 Down from CN¥105, the current price target is an average from 4 analysts. New target price is 27% above last closing price of CN¥71.24. Stock is down 27% over the past year. The company is forecast to post earnings per share of CN¥2.24 for next year compared to CN¥1.87 last year. Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 5 non-independent directors. Independent Director Wei Dong was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Valuation Update With 7 Day Price Move • Nov 04
Investor sentiment improved over the past week After last week's 15% share price gain to CN¥69.70, the stock trades at a forward P/E ratio of 31x. Average forward P/E is 29x in the Biotechs industry in China. Simply Wall St's valuation model estimates the intrinsic value at CN¥119 per share. Reported Earnings • Oct 30
Third quarter 2022 earnings released: EPS: CN¥0.34 (vs CN¥0.44 in 3Q 2021) Third quarter 2022 results: EPS: CN¥0.34 (down from CN¥0.44 in 3Q 2021). Revenue: CN¥685.3m (up 48% from 3Q 2021). Net income: CN¥135.8m (down 14% from 3Q 2021). Profit margin: 20% (down from 34% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 7.6% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in China. Valuation Update With 7 Day Price Move • Oct 19
Investor sentiment improved over the past week After last week's 16% share price gain to CN¥62.65, the stock trades at a forward P/E ratio of 28x. Average forward P/E is 29x in the Biotechs industry in China. Valuation Update With 7 Day Price Move • Sep 22
Investor sentiment deteriorated over the past week After last week's 16% share price decline to CN¥59.23, the stock trades at a forward P/E ratio of 26x. Average forward P/E is 27x in the Biotechs industry in China. Reported Earnings • Aug 26
Second quarter 2022 earnings released Second quarter 2022 results: EPS: CN¥0.45. Net income: CN¥182.6m (up CN¥182.6m from 2Q 2021). Over the next year, revenue is expected to shrink by 2.7% compared to a 33% growth forecast for the Biotechs industry in China. Reported Earnings • Apr 27
First quarter 2022 earnings: EPS and revenues exceed analyst expectations First quarter 2022 results: EPS: CN¥1.08. Revenue: CN¥975.3m (flat on 1Q 2021). Net income: CN¥431.4m (up CN¥431.4m from 1Q 2021). Profit margin: 44% (up from null in 1Q 2021). Revenue exceeded analyst estimates by 7.6%. Earnings per share (EPS) also surpassed analyst estimates by 11%. Over the next year, revenue is forecast to grow 12%, compared to a 44% growth forecast for the industry in China. Buying Opportunity • Mar 16
Now 27% undervalued after recent price drop Over the last 90 days, the stock is down 13%. The fair value is estimated to be CN¥137, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 66% per annum over the last 3 years. Earnings per share has declined by 19% over the last year. Valuation Update With 7 Day Price Move • Mar 11
Investor sentiment improved over the past week After last week's 22% share price gain to CN¥106, the stock trades at a forward P/E ratio of 55x. Average forward P/E is 32x in the Biotechs industry in China. Simply Wall St's valuation model estimates the intrinsic value at CN¥136 per share. Reported Earnings • Feb 28
Full year 2021 earnings: EPS and revenues exceed analyst expectations Full year 2021 results: EPS: CN¥1.87 (down from CN¥2.31 in FY 2020). Revenue: CN¥1.86b (up 19% from FY 2020). Net income: CN¥678.5m (down 17% from FY 2020). Profit margin: 36% (down from 53% in FY 2020). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 7.3%. Earnings per share (EPS) also surpassed analyst estimates by 11%. Over the next year, revenue is forecast to grow 3.1%, compared to a 37% growth forecast for the pharmaceuticals industry in China. Valuation Update With 7 Day Price Move • Jan 21
Investor sentiment deteriorated over the past week After last week's 20% share price decline to CN¥86.11, the stock trades at a forward P/E ratio of 50x. Average forward P/E is 34x in the Biotechs industry in China.